{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:08:49Z","timestamp":1793394529961,"version":"4.5.0"},"reference-count":110,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP210234"],"award-info":[{"award-number":["RP210234"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies due to late diagnosis and limited treatment options. Circulating tumor DNA (ctDNA) is a promising, minimally invasive biomarker that could improve the clinical outcomes of patients with PDAC by enabling early disease detection, minimal residual disease (MRD) assessment, precise prognostication, and accurate treatment monitoring. CtDNA has prognostic as well as predictive value in both resectable and metastatic settings, with serial measurements enhancing risk stratification and recurrence prediction beyond CA19-9. However, despite the promise, the true potential of ctDNA has not yet been fulfilled in patients with PDAC. The current limitations include a low sensitivity of ctDNA assays in early stage PDAC, challenges in the assay interpretation due to the specific nature of ctDNA shedding in PDAC, inter-patient heterogeneity, and technical variability. As precision oncology advances, ctDNA will be a powerful tool for personalized care in PDAC, but rigorous validation of its use within specific clinical contexts is still needed before the true potential of ctDNA is realized for patients with PDAC.<\/jats:p>","DOI":"10.3390\/curroncol32110589","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T05:20:44Z","timestamp":1761196844000},"page":"589","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["ctDNA in Pancreatic Adenocarcinoma: A Critical Appraisal"],"prefix":"10.3390","volume":"32","author":[{"given":"Sujata","family":"Ojha","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Dell Medical School, University of Texas at Austin, Austin, TX 78712, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sessions","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Dell Medical School, University of Texas at Austin, Austin, TX 78712, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Dell Medical School, University of Texas at Austin, Austin, TX 78712, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyaw L.","family":"Aung","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Dell Medical School, University of Texas at Austin, Austin, TX 78712, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12957-021-02478-x","article-title":"Prognosis and survival analysis of patients with pancreatic cancer: Retrospective experience of a single institution","volume":"20","author":"Li","year":"2022","journal-title":"World J. Surg. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2020.11.040","article-title":"A review of lifestyle and environment risk factors for pancreatic cancer","volume":"145","author":"Zanini","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s41416-021-01469-9","article-title":"BRCA-mutant pancreatic ductal adenocarcinoma","volume":"125","author":"Lai","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-022-01710-w","article-title":"Circulating tumor nucleic acids: Biology, release mechanisms, and clinical relevance","volume":"22","author":"Stejskal","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Herrero, E., Serna-Blasco, R., Robado de Lope, L., Gonz\u00e1lez-Rumayor, V., Romero, A., and Provencio, M. (2022). Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.943253"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: Towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"105109","DOI":"10.1016\/j.ebiom.2024.105109","article-title":"Circulating tumour DNA-Based molecular residual disease detection in resectable cancers: A systematic review and meta-analysis","volume":"103","author":"Zheng","year":"2024","journal-title":"eBioMedicine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41586-018-0703-0","article-title":"Sensitive tumour detection and classification using plasma cell-free DNA methylomes","volume":"563","author":"Shen","year":"2018","journal-title":"Nature"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1038\/s41598-024-56419-1","article-title":"Precision cancer classification using liquid biopsy and advanced machine learning techniques","volume":"14","author":"Eledkawy","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41416-021-01624-2","article-title":"Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: Post-hoc analyses of two clinical trials","volume":"126","author":"Pietrasz","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1158\/1078-0432.CCR-22-3526","article-title":"Comprehensive ctDNA Measurements Improve Prediction of Clinical Outcomes and Enable Dynamic Tracking of Disease Progression in Advanced Pancreatic Cancer","volume":"29","author":"Lapin","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e0235623","DOI":"10.1371\/journal.pone.0235623","article-title":"Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis","volume":"15","author":"Uesato","year":"2020","journal-title":"PLoS ONE"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/ijc.32586","article-title":"Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma","volume":"146","author":"Strijker","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"926260","DOI":"10.3389\/fonc.2022.926260","article-title":"Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma","volume":"12","author":"Guan","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"103528","DOI":"10.1016\/j.critrevonc.2021.103528","article-title":"A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer","volume":"168","author":"Guven","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1097\/SLA.0000000000006209","article-title":"Prospective Evaluation of Circulating Tumor DNA Using Next-generation Sequencing as a Biomarker During Neoadjuvant Chemotherapy in Localized Pancreatic Cancer","volume":"281","author":"Shah","year":"2025","journal-title":"Ann. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"97769","DOI":"10.18632\/oncotarget.22080","article-title":"Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/SLA.0000000000006468","article-title":"New Biomarkers to Define a Biological Borderline Situation for Pancreatic Adenocarcinoma: Results of an Ancillary Study of the PANACHE01-PRODIGE48 Trial","volume":"280","author":"Pinson","year":"2024","journal-title":"Ann. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1382369","DOI":"10.3389\/fonc.2024.1382369","article-title":"Evaluation of the diagnostic and prognostic clinical values of circulating tumor DNA and cell-free DNA in pancreatic malignancies: A comprehensive meta-analysis","volume":"14","author":"Arayici","year":"2024","journal-title":"Front. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.21873\/anticanres.15886","article-title":"Prognostic Role of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 in Stage IV Colorectal Cancer","volume":"42","author":"Kawamura","year":"2022","journal-title":"Anticancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/oncolo\/oyae155","article-title":"Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma","volume":"29","author":"Botta","year":"2024","journal-title":"Oncologist"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1186\/s12885-018-4663-4","article-title":"Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy-a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)","volume":"18","author":"Schwarz","year":"2018","journal-title":"BMC Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/bjc.2017.250","article-title":"Diagnostic value of CA19.9, circulating tumour DNA and circulating tumour cells in patients with solid pancreatic tumours","volume":"117","author":"Sefrioui","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"188409","DOI":"10.1016\/j.bbcan.2020.188409","article-title":"Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter","volume":"1875","author":"Luo","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/MEG.0000000000002415","article-title":"Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: A systematic review and meta-analysis","volume":"34","author":"Zhao","year":"2022","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1053\/j.gastro.2020.11.052","article-title":"Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection","volume":"160","author":"Fahrmann","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mason, J., Lundberg, E., Jonsson, P., Nystr\u00f6m, H., Franklin, O., Lundin, C., Naredi, P., Antti, H., Sund, M., and \u00d6hlund, D. (2022). A Cross-Sectional and Longitudinal Analysis of Pre-Diagnostic Blood Plasma Biomarkers for Early Detection of Pancreatic Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232112969"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Zheng, Z., Lu, Z., Yan, F., and Song, Y. (2025). The role of novel biomarkers in the early diagnosis of pancreatic cancer: A systematic review and meta-analysis. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0322720"},{"key":"ref_32","first-page":"639","article-title":"Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer","volume":"73","author":"Wang","year":"2024","journal-title":"Gut"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1634\/theoncologist.2014-0408","article-title":"Allelic Ratio of KRAS Mutations in Pancreatic Cancer","volume":"20","author":"Lennerz","year":"2015","journal-title":"Oncologist"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Zhang, H., Liao, X., and Tsai, H. (2023). KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1147676"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/clinchem\/hvac214","article-title":"Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma","volume":"69","author":"Nitschke","year":"2023","journal-title":"Clin. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1196\/annals.1368.027","article-title":"Comparative analysis of mesenteric and peripheral blood circulating tumor DNA in colorectal cancer patients","volume":"1075","author":"Taback","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/clinchem\/hvac153","article-title":"Parallel Analysis of Pre- and Postoperative Circulating Tumor DNA and Matched Tumor Tissues in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Cohort Study","volume":"68","author":"Lee","year":"2022","journal-title":"Clin. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-19-0197","article-title":"Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer","volume":"25","author":"Groot","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Jiang, J., Ye, S., Xu, Y., Chang, L., Hu, X., Ru, G., Guo, Y., Yi, X., Yang, L., and Huang, D. (2020). Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01220"},{"key":"ref_40","first-page":"741","article-title":"Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma","volume":"22","author":"Ueberroth","year":"2022","journal-title":"Pancreatol. Off. J. Int. Assoc. Pancreatol. IAP Al"},{"key":"ref_41","unstructured":"(2025, April 21). The Circulating Cell-Free Genome Atlas (CCGA) Study. GRAIL. Available online: https:\/\/grail.com\/clinical-studies\/ccga-study\/."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating Tumor DNA Analysis in Patients with Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review","volume":"36","author":"Merker","year":"2018","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1097\/MPA.0000000000002239","article-title":"Circulating Tumor DNA Is an Accurate Diagnostic Tool and Strong Prognostic Marker in Pancreatic Cancer","volume":"52","author":"Sellahewa","year":"2023","journal-title":"Pancreas"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"102028","DOI":"10.1016\/j.ctrv.2020.102028","article-title":"Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review","volume":"87","author":"Abdallah","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Wang, Z.-Y., Ding, X.-Q., Zhu, H., Wang, R.-X., Pan, X.-R., and Tong, J.-H. (2019). KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates with Clinical Stage in Pancreatic Cancer Patients. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01295"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1056\/NEJMra2309041","article-title":"Pancreatic Cysts","volume":"391","author":"Gonda","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.3748\/wjg.v25.i36.5530","article-title":"Genomic profile concordance between pancreatic cyst fluid and neoplastic tissue","volume":"25","author":"Lagarde","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/ajg.2018.14","article-title":"ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts","volume":"113","author":"Elta","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Chidharla, A., Rapoport, E., Agarwal, K., Madala, S., Linares, B., Sun, W., Chakrabarti, S., and Kasi, A. (2023). Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210230"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/ijc.35442","article-title":"Utility of circulating tumor DNA to detect minimal residual disease in colorectal cancer: A systematic review and network meta-analysis","volume":"157","author":"Hoang","year":"2025","journal-title":"Int. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41416-023-02300-3","article-title":"Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer","volume":"129","author":"Ryoo","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1158\/1078-0432.CCR-24-0226","article-title":"Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study","volume":"30","author":"Slater","year":"2024","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/annonc\/mdz390","article-title":"Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer","volume":"30","author":"Tarazona","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Negro, S., Pulvirenti, A., Trento, C., Indraccolo, S., Ferrari, S., Scarpa, M., Urso, E.D.L., Bergamo, F., Pucciarelli, S., and Deidda, S. (2025). Circulating Tumor DNA as a Real-Time Biomarker for Minimal Residual Disease and Recurrence Prediction in Stage II Colorectal Cancer: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26062486"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2023.11.009","article-title":"Unraveling the potential clinical utility of circulating tumor DNA detection in colorectal cancer-evaluation in a nationwide Danish cohort","volume":"35","author":"Henriksen","year":"2024","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1158\/1078-0432.CCR-23-3660","article-title":"Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment","volume":"30","author":"Parikh","year":"2024","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1200\/JCO.21.02615","article-title":"Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices","volume":"40","author":"Malla","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Chakrabarti, S., Kasi, A.K., Parikh, A.R., and Mahipal, A. (2022). Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC). Cancers, 14.","DOI":"10.20944\/preprints202205.0368.v1"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"bgae073","DOI":"10.1093\/carcin\/bgae073","article-title":"Prognostic value of circulating tumor DNA in different cancer types detected by ultra-low-pass whole-genome sequencing: A systematic review and patient-level survival data meta-analysis","volume":"46","author":"Sogbe","year":"2025","journal-title":"Carcinogenesis"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejca.2021.09.019","article-title":"Circulating tumour DNA (ctDNA) in metastatic melanoma, a systematic review and meta-analysis","volume":"158","author":"Gracie","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"103187","DOI":"10.1016\/j.critrevonc.2020.103187","article-title":"Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis","volume":"157","author":"Gandini","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e0171991","DOI":"10.1371\/journal.pone.0171991","article-title":"Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review","volume":"12","author":"Fan","year":"2017","journal-title":"PLoS ONE"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1158\/1055-9965.EPI-15-0893","article-title":"Circulating DNA and Survival in Solid Tumors","volume":"25","author":"Templeton","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1200\/JCO.2024.42.3_suppl.695","article-title":"Utility of circulating tumor DNA (ctDNA) for the detection of minimal residual disease (MRD) after curative-intent therapy for patients with localized pancreatic adenocarcinoma (PDAC): A single institution series and meta-analysis","volume":"42","author":"Yanala","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/annonc\/mdz200","article-title":"Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer","volume":"30","author":"Lee","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"16971","DOI":"10.1038\/s41598-019-53271-6","article-title":"Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis","volume":"9","author":"Lee","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"102604","DOI":"10.1016\/j.ctrv.2023.102604","article-title":"Liquid biopsy after resection of pancreatic adenocarcinoma and its relation to oncological outcomes. Systematic review and meta-analysis","volume":"120","author":"Vidal","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/jhbp.1282","article-title":"Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection","volume":"30","author":"Hata","year":"2023","journal-title":"J. Hepato-Biliary-Pancreat. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.3748\/wjg.v27.i22.3037","article-title":"Role of imaging in evaluating the response after neoadjuvant treatment for pancreatic ductal adenocarcinoma","volume":"27","author":"Zhang","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"570","DOI":"10.2214\/AJR.21.26931","article-title":"Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy: AJR Expert Panel Narrative Review","volume":"218","author":"Soloff","year":"2022","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2214\/AJR.20.24567","article-title":"Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET\/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival","volume":"217","author":"Panda","year":"2021","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Vitello, D.J., Shah, D., Wells, A., Masnyk, L., Cox, M., Janczewski, L.M., Abad, J., Dawravoo, K., D\u2019Souza, A., and Suh, G. (2024). Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer in Patients Treated with Neoadjuvant Chemotherapy. Ann. Surg.","DOI":"10.1097\/SLA.0000000000006562"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1245\/s10434-021-10985-0","article-title":"Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by Pancreatectomy","volume":"29","author":"Kitahata","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"11542","DOI":"10.1038\/s41598-019-47708-1","article-title":"Correlation between early dynamics in circulating tumour DNA and outcome from FOLFIRI treatment in metastatic colorectal cancer","volume":"9","author":"Kronborg","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41416-022-01837-z","article-title":"Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment","volume":"127","author":"Kim","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1158\/1078-0432.CCR-24-0924","article-title":"Circulating Tumor DNA Dynamics and Clinical Outcome in Metastatic Colorectal Cancer Patients Undergoing Front-Line Chemotherapy","volume":"31","author":"Ghidini","year":"2025","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/cas.14245","article-title":"Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy","volume":"111","author":"Sugimori","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/carcin\/bgaa102","article-title":"Circulating tumor DNA is a sensitive marker for routine monitoring of treatment response in advanced colorectal cancer","volume":"41","author":"Zou","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e2100512","DOI":"10.1200\/PO.21.00512","article-title":"Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers","volume":"6","author":"Gouda","year":"2022","journal-title":"JCO Precis. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1158\/1078-0432.CCR-23-1578","article-title":"Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung Cancer","volume":"29","author":"Pellini","year":"2023","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/JP9.0000000000000001","article-title":"Conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma: Where do we stand in 2018?","volume":"1","author":"Satoi","year":"2018","journal-title":"J. Pancreatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/onco.13717","article-title":"Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma","volume":"26","author":"Botrus","year":"2021","journal-title":"Oncologist"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"djaf139","DOI":"10.1093\/jnci\/djaf139","article-title":"Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma","volume":"117","author":"Keane","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12885-022-09387-6","article-title":"Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer","volume":"22","author":"Sivapalan","year":"2022","journal-title":"BMC Cancer"},{"key":"ref_85","first-page":"363","article-title":"Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application","volume":"21","author":"Sivapalan","year":"2021","journal-title":"Pancreatol. Off. J. Int. Assoc. Pancreatol. IAP Al"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jhep.2024.10.020","article-title":"Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer","volume":"82","author":"Hwang","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2403334","DOI":"10.1080\/20450923.2024.2403334","article-title":"Integration of circulating tumor DNA in biliary tract cancer: The emerging landscape","volume":"11","author":"Awosika","year":"2024","journal-title":"Hepatic Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"16203","DOI":"10.1038\/s41598-024-67235-y","article-title":"Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinoma","volume":"14","author":"Labiano","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.annonc.2023.01.008","article-title":"Clinical utility of circulating tumor DNA sequencing with a large panel: A National Center for Precision Medicine (PRISM) study","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_90","unstructured":"Gahan, P.B., Fleischhacker, M., and Schmidt, B. (2016). Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer. Circulating Nucleic Acids in Serum and Plasma\u2013CNAPS IX, Springer International Publishing."},{"key":"ref_91","first-page":"114186","article-title":"Exploring the biology of ctDNA release in colorectal cancer","volume":"207","author":"Andersen","year":"2024","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e0256436","DOI":"10.1371\/journal.pone.0256436","article-title":"Clinical correlates of circulating cell-free DNA tumor fraction","volume":"16","author":"Bredno","year":"2021","journal-title":"PLoS ONE"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e0230622","DOI":"10.1371\/journal.pone.0230622","article-title":"Clinicopathological parameters for circulating tumor DNA shedding in surgically resected non-small cell lung cancer with EGFR or KRAS mutation","volume":"15","author":"Cho","year":"2020","journal-title":"PLoS ONE"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e0319194","DOI":"10.1371\/journal.pone.0319194","article-title":"The role of renal and liver function in clinical ctDNA testing","volume":"20","author":"Andersen","year":"2025","journal-title":"PLoS ONE"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1007\/s11033-021-06962-1","article-title":"Personalized circulating tumor DNA in patients with hepatocellular carcinoma: A pilot study","volume":"49","author":"Pommergaard","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e0266889","DOI":"10.1371\/journal.pone.0266889","article-title":"Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panels","volume":"17","author":"Yu","year":"2022","journal-title":"PLoS ONE"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","article-title":"Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology","volume":"39","author":"Deveson","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.trecan.2023.08.011","article-title":"Variant allele frequency: A decision-making tool in precision oncology?","volume":"9","author":"Trapani","year":"2023","journal-title":"Trends Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e154941","DOI":"10.1172\/JCI154941","article-title":"Circulating tumor DNA: Current challenges for clinical utility","volume":"132","author":"Dang","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"609","DOI":"10.6004\/jnccn.2023.7011","article-title":"Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment","volume":"21","author":"Douglas","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/clinchem\/hvac121","article-title":"Circulating Tumor DNA as a Biomarker for Monitoring Patients with Solid Cancers: Comparison with Standard Protein Biomarkers","volume":"68","author":"Duffy","year":"2022","journal-title":"Clin. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Arisi, M.F., Dotan, E., and Fernandez, S.V. (2022). Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084441"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of Cell-free DNA Analysis to Cancer Treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s10555-020-09876-9","article-title":"Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy","volume":"39","author":"Boonstra","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e2400489","DOI":"10.1200\/PO-24-00489","article-title":"Incorporating Circulating Tumor DNA Testing into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group","volume":"9","author":"Rajdev","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_106","unstructured":"Antolino, L. (2025, June 17). Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis. Clinicaltrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03524677."},{"key":"ref_107","unstructured":"Westphalen, B. (2025, June 17). Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer. Clinicaltrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04246203."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Grunvald, M.W., Jacobson, R.A., Kuzel, T.M., Pappas, S.G., and Masood, A. (2020). Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207651"},{"key":"ref_109","unstructured":"(2025, June 17). National Cancer Institute (NCI) APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation; clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04858334."},{"key":"ref_110","unstructured":"(2025, June 17). University Hospital, Essen Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients; clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05298072."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/11\/589\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T06:20:49Z","timestamp":1761200449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/11\/589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":110,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["curroncol32110589"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32110589","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]}}}